Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyroglutamate-modified Amyloid Beta (N-terminal Truncated) (AβpE)
- Target
- AβpE
- Molecular classification
- Peptide, Amyloid beta peptide, Modified peptide
01
Overview
Pyroglutamate-modified amyloid beta represents a highly pathogenic subset of amyloid-beta peptides characterized by N-terminal truncation and conversion of the third amino acid residue into pyroglutamic acid. This modification enhances peptide aggregation, stability against degradation, membrane-disruptive activity, and neurotoxicity—making it a significant contributor to Alzheimer’s disease pathology and an important target for biomarker development or therapeutic intervention.
- Other names
- pE-AβAmyloid beta pyroglutamateAβpE3-40AβpE3-42Pyroglutamate Aβ
02
Mechanism of action
Inhibition of aggregation, Promotion of degradation, Antibody-mediated clearance, Inhibition of glutaminyl cyclase
03
Biological functions
Amyloid formationNeurotoxicityMembrane disruptionAggregation
04
Disease associations
Alzheimer's diseaseNeurodegenerative disease
05
Safety considerations
Potential for off-target effects of glutaminyl cyclase inhibitorsImmunogenicity of antibody-based therapiesInflammationVasogenic edema
06
Biomarkers
Cerebrospinal fluid levels of pE-AβPlaque burden of pE-Aβ
Beyond the preview
Go deeper on Pyroglutamate-modified Amyloid Beta (N-terminal Truncated) (AβpE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pyroglutamate-modified Amyloid Beta (N-terminal Truncated) (AβpE).